China SXT Pharmaceuticals (FRA:2RY2) Net Income (Continuing Operations): €-5.28 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2RY2 China SXT Pharmaceuticals Inc FRA:2RY2
19 GF Score
Price €3.04
GF Value €5.74
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Net Income (Continuing Operations)?

China SXT Pharmaceuticals FRA:2RY2 -2.38% 19 Net Income (Continuing Operations) is €-5.28 Mil as of Mar. 2026. GuruFocus rates FRA:2RY2 with a GF Score™ of 19/100 and a GF Value™ of €5.74 (Possible Value Trap). The stock has 8 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. China SXT Pharmaceuticals's Net Income (Continuing Operations) for the six months ended in Mar. 2026 was €0.14 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 was €-5.28 Mil.

China SXT Pharmaceuticals  (FRA:2RY2) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

China SXT Pharmaceuticals Net Income (Continuing Operations) Related Terms

China SXT Pharmaceuticals Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for China SXT Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China SXT Pharmaceuticals Net Income (Continuing Operations) Chart

China SXT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.21 -5.54 -2.85 -3.06 -5.37

China SXT Pharmaceuticals Semi-Annual Data
Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.07 -0.72 -2.31 -5.43 0.14
FRA:2RY2
19GF Score
China SXT Pharmaceuticals Inc FRA:2RY2
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China SXT Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-5.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €-5.28 Mil mean?
China SXT Pharmaceuticals (FRA:2RY2) has a Net Income (Continuing Operations) of €-5.28 Mil as of Mar. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on China SXT Pharmaceuticals and its competitors.
Is China SXT Pharmaceuticals' Net Income (Continuing Operations) too high?
China SXT Pharmaceuticals' current Net Income (Continuing Operations) is €-5.28 Mil. Overall, China SXT Pharmaceuticals has a GF Score™ of 19/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' Net Income (Continuing Operations) compare to CBIH and UPC?
China SXT Pharmaceuticals' Net Income (Continuing Operations) of €-5.28 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on China SXT Pharmaceuticals and its competitors. China SXT Pharmaceuticals's current Net Income (Continuing Operations) is €-5.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, China SXT Pharmaceuticals (FRA:2RY2) is currently considered Possible Value Trap. The stock's GF Value™ is €5.74, compared to a current price of €3.04 — trading 47.1% below its estimated fair value. The current Net Income (Continuing Operations) is €-5.28 Mil. China SXT Pharmaceuticals' overall GF Score™ is 19/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For China SXT Pharmaceuticals (FRA:2RY2), the current Net Income (Continuing Operations) is €-5.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China SXT Pharmaceuticals (FRA:2RY2) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued. The current stock price of €3.04 is trading 47.1% below its estimated GF Value™ of €5.74. GuruFocus considers China SXT Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:2RY2:

  • Net Income (Continuing Operations): €-5.28 Mil
  • GF Value™: €5.74 vs. price of €3.04 (47.1% below fair value)
  • GF Score™: 19/100 with 8 warning signs

No single metric tells the full story. See the FRA:2RY2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score

Get the complete analysis for FRA:2RY2

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€5.74
GF Value